

NON-EXECUTIVE DIRECTOR RETIREMENT

Simon Arkell retires from LBT Board

Adelaide, Australia, 30 March 2023: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, advises of the retirement of Non-Executive Director, Mr Simon Arkell, from the LBT Board (the **Board**), effective today.

Simon joined the Board in January 2019, and during this time has supported the Company's technology development strategy as the Company has expanded the commercial application of the APAS® technology into the pharmaceutical industry market. The Board is reviewing its current skills matrix as well as future requirements for the Company before commencing a recruitment process for a new Director.

LBT Chair, Ms Joanne Moss said:

"On behalf of the Board, I would like to thank Simon for his contribution to the Company over the past 4 years. He has provided valued input towards the Company's technology commercialisation strategy as well as an international focus to the Board. We wish Simon all the best in the future."

An Appendix 3Z for Mr Arkell is also filed with this Announcement.

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company's second product, the Automated Plate Assessment System (APAS® Independence) uses LBT's intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

LBT Innovations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	LBT INNOVATIONS LTD
ABN	95 107 670 673

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Mr Simon Arkell
Date of last notice	2 December 2022
Date that director ceased to be director	29 March 2023

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
213,813 Ordinary Shares
500,000 Unlisted Options (exercise price \$0.08, expiring 28 November 2029)

+ See chapter 19 for defined terms.

Appendix 3Z Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of securities
Note: Provide details of the circumstances giving rise to the relevant interest	
N/A	N/A

Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.